Stoke Therapeutics News

Express News | Stoke Therapeutics Inc Files for Shelf of up to 10.8 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

ReutersJun 13 16:07 ET

Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec

Simply Wall StJun 11 06:55 ET

Stoke Therapeutics(STOK.US) Officer Sells US$152.19K in Common Stock

$Stoke Therapeutics(STOK.US)$ Officer Ticho Barry sold 10,000 shares of common stock on Jun 3, 2024 at an average price of $15.2185 for a total value of $152.19K.Source: Announcement What is statement

moomoo NewsJun 5 17:01 ET

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 3, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein

Stoke TherapeuticsJun 3 00:00 ET

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

Yahoo FinanceMay 22 19:07 ET

Stoke Therapeutics(STOK.US) Officer Sells US$769.5K in Common Stock

$Stoke Therapeutics(STOK.US)$ Officer Nash Huw M. sold 50,000 shares of common stock on May 20, 2024 at an average price of $15.39 for a total value of $769.5K.Source: Announcement What is statement o

moomoo NewsMay 22 17:03 ET

Stoke Therapeutics(STOK.US) Officer Sells US$653.53K in Common Stock

$Stoke Therapeutics(STOK.US)$ Officer Kaye Edward M. MD sold 42,350 shares of common stock on May 20, 2024 at an average price of $15.4316 for a total value of $653.53K.Source: Announcement What is st

moomoo NewsMay 22 17:01 ET

Stoke Therapeutics(STOK.US) Officer Sells US$129.33K in Common Stock

$Stoke Therapeutics(STOK.US)$ Officer Allan Jonathan sold 8,599 shares of common stock on May 20, 2024 at an average price of $15.0398 for a total value of $129.33K.Source: Announcement What is statem

moomoo NewsMay 22 16:59 ET

Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing

Edward M. Kaye, Director, CEO, on May 20, 2024, sold 42,350 shares in Stoke Therapeutics (STOK) for $653,529. Following the Form 4 filing with the SEC, Kaye has control over a total of 27,000 shares o

MT NewswiresMay 22 16:25 ET

Form 144 | Stoke Therapeutics(STOK.US) Officer Proposes to Sell 119.53K in Common Stocks

SEC FILLINGS DISCLOSED/ May 20, $Stoke Therapeutics(STOK.US)$ Officer JONATHAN ALLAN intends to sell 8,599 shares of its common stock on May 20, with a total market value of approximately $119.53K.

moomoo NewsMay 20 16:29 ET

Form 144 | Stoke Therapeutics(STOK.US) Officer Proposes to Sell 695K in Common Stocks

SEC FILLINGS DISCLOSED/ May 20, $Stoke Therapeutics(STOK.US)$ Officer HUW MICHAEL NASH intends to sell 50,000 shares of its common stock on May 20, with a total market value of approximately $695K.

moomoo NewsMay 20 16:28 ET

Form 144 | Stoke Therapeutics(STOK.US) Director Proposes to Sell 588.67K in Common Stocks

SEC FILLINGS DISCLOSED/ May 20, $Stoke Therapeutics(STOK.US)$ Director EDWARD M KAYE intends to sell 42,350 shares of its common stock on May 20, with a total market value of approximately $588.67K.

moomoo NewsMay 20 16:28 ET

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--May 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein

Stoke TherapeuticsMay 17 00:00 ET

Buy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial Stability

TipRanksMay 7 23:57 ET

Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...

Yahoo FinanceMay 7 21:04 ET

Stoke Therapeutics Is Maintained at Buy by Canaccord Genuity

Stoke Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 7 10:29 ET

Stoke Therapeutics Price Target Cut to $20.00/Share From $21.00 by Canaccord Genuity

Stoke Therapeutics Price Target Cut to $20.00/Share From $21.00 by Canaccord Genuity

Dow JonesMay 7 10:29 ET

Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)

TipRanksMay 7 08:50 ET

Express News | HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target

BenzingaMay 7 08:06 ET

Buy Rating for Stoke Therapeutics With Adjusted Price Target Amid Regulatory and Developmental Progress

TipRanksMay 7 07:53 ET